HypertensionNCT06961981
Remote Vinyasa Yoga Program for Heart Health
A study testing Vinyasa Yoga in people with Hypertension and Cardiovascular Diseases, run by West Virginia University at 1 site in United States.
Trial summary
The purpose of this study is to test a 12-week vinyasa yoga (flow yoga) intervention via Zoom. This program will be for 30 individuals with high blood pressure. 15 will receive the intervention and 15 will follow their usual routine. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Hypertension, Cardiovascular Diseases
- What is being tested?
- Vinyasa Yoga
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2025to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals with a resting systolic BP >120 mmHg
Who cannot join
- Report currently meeting aerobic activity guidelines (150 min/wk)
- Practice yoga regularly (1 or more day/wk in the past month)
- Have physical limitations or a major medical condition contraindicating yoga or assessments
- Have uncontrolled HTN (systolic BP 160 mmHg or diastolic BP 100 mmHg)
- Are currently pregnant or planning to become pregnant within 6 months
- Are not on a stable dose of medications that could affect study outcomes
- Are concurrently enrolled in another lifestyle program
- No vulnerable populations will be included
Trial locations and contacts
1 site in 1 country.
United States1 site
West Virginia University
Morgantown, West Virginia, 26506
About this study
Official title: Feasibility, Acceptability, and Preliminary Efficacy of a Remote Vinyasa Yoga Program for Heart Health
The purpose of this study is to test a 12-week vinyasa yoga (flow yoga) intervention via Zoom. This program will be for 30 individuals with high blood pressure. 15 will receive the intervention and 15 will follow their usual routine. The investigators will determine if this vinyasa yoga program is feasible and acceptable in this population. Investigators will measure and compare blood pressure and other health responses such as physical health and well-being before and after participants complete the intervention or usual care period. The investigators hope to demonstrate that vinyasa yoga is a good option to improve heart health in people with high blood pressure.
Primary Objective - Examine the feasibility, acceptability, and preliminary efficacy of a 12-wk remotely-delivered vinyasa yoga intervention (3 x per week) on cardiovascular (CV) health in adults with hypertension (HTN).
- Conditions
- Hypertension, Cardiovascular Diseases
- Being tested
- Vinyasa Yoga
- Keywords
- Yoga, vinyasa yoga
- Medical subject headings
- Hypertension, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vinyasa YogaBehavioural
Also called Flow Yoga
Each yoga session will begin with 2 minutes of integration poses (Child's Pose, Downward Facing Dog, Ragdoll, and Mountain Pose), followed by ~20 minutes of Sun Salutations A and B (up to 5 of each). The Standing Series, lasting ~25 minutes, will include various standing and balancing poses from the Journey into Power sequence. Seated and supine stretches (including seated stretches, a yoga inversion, a reclined twist) will last ~8 minutes, and the session will conclude with 5 minutes of Savasana for final relaxation.
| Study group | Role | What they receive |
|---|---|---|
| Vinyasa Yoga | Experimental | Participants will complete a 12-week, remotely-delivered intervention with three 60-minute vinyasa yoga sessions per week via Zoom, following an adapted Journey into Power yoga sequence by Baron Baptiste. The sessions will incorporate three mind-body components of yoga: through physical yoga poses, mindfulness, and breathing. Receives: Behavioral: Vinyasa Yoga |
| Standard Routine | No intervention | Standard usual routine for 12 weeks |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Carotid-Femoral Pulse Wave Velocity
Change from baseline to 12 weeks. Measure of central arterial stiffness (meters/second) measured by oscilometiric pulse wave velocity. A value of 10 m/s and above is classified as an unfavorable value.
Measured: Baseline to 12 weeks
Secondary outcomes (29)
Change in systolic blood pressure
Change from baseline to 12 weeks. Measure of pressure in the arteries when the heart beats (millimeters of mercury) measured by an automated blood pressure device with an oscillometric cuff. A value of less than 120 mmHg is considered normal, elevated is a value 120-129 mmHg, and high blood pressure is any value 130 or above.
Measured: Baseline to 12 weeks
Change in diastolic blood pressure
Change from baseline to 12 weeks. Measure of pressure in the arteries between heart beats (millimeters of mercury) measured by an automated blood pressure device with an oscillometric cuff. A value of less than 80 mmHg is considered normal, and high blood pressure is any value 80 or above.
Measured: Baseline to 12 weeks
Change in augmentation pressure
Change from baseline to 12 weeks. Difference in pressure (millimeters of mercury) measured by oscilometiric pulse wave analysis. A value between 20 and 80 mmHg is considered within the normal range, while values at or above 80 mmHg are regarded as unfavorable and may indicate increased cardiovascular risk.
Measured: Baseline to 12 weeks
Change in augmentation index
Change from baseline to 12 weeks. Measure of systemic arterial stiffness (%), measured by oscillometric pulse wave analysis. A value under 33% is considered normal while a value above 33% is considered unfavorable.
Measured: Baseline to 12 weeks
Change in mean heart rate
Change from Baseline to 12 weeks. Measure of the number of heart beats in a minute (beats per minute) measured by a heart rate sensor. A value below 100 is considered normal while values above 100 are unfavorable.
Measured: Baseline to 12 weeks
Change in standard deviation of normal R-R Intervals
Change from Baseline to 12 weeks. A measure of heart rate variability measuring overall variation between R-R intervals (milliseconds) measured by a heart rate sensor recording R-R intervals. Typically, a higher value is considered better for this outcome while a lower value is considered unfavorable.
Measured: Baseline to 12 weeks
Change in root mean square of successive differences
Change from Baseline to 12 weeks. A measure of heart rate variability measuring variability and parasympathetic activity (milliseconds) measured by a heart rate sensor recording R-R intervals. Typically, a higher value is considered better for this outcome while a lower value is considered unfavorable.
Measured: Baseline to 12 weeks
Change in high frequency heart rate variability
Change from Baseline to 12 weeks. A measure of heart rate variability measuring parasympathetic nervous system activity (milliseconds squared) measured by a heart rate sensor recording R-R intervals. Typically, a higher value is considered better for this outcome while a lower value is considered unfavorable.
Measured: Baseline to 12 weeks
Change in low frequency heart rate variability
Change from Baseline to 12 weeks. A measure of heart rate variability measuring sympathetic nervous system activity (milliseconds squared) measured by a heart rate sensor recording R-R intervals. Typically, a lower value is considered better for this outcome while a higher value is considered unfavorable.
Measured: Baseline to 12 weeks
Change in low frequency to high frequency ratio
Change from Baseline to 12 weeks. A measure of heart rate variability measuring the ratio of sympathetic and parasympathetic nervous system activity (unitless) measured by a heart rate sensor recording R-R intervals. Typically, a lower value is considered better for this outcome while a higher value is considered unfavorable.
Measured: Baseline to 12 weeks
Change in body mass index
Change from Baseline to 12 weeks. A measure of body fat based on height and weight (kilograms per meters squared) measured by height (stadiometer) and weight (scale). An individual is considered underweight if their BMI is <18.5 kg/m2, normal weight if their BMI ranges from 18.5 to 24.9 kg/m2, overweight if their BMI ranges from 25-29.9 kg/m2, and obese if their BMI is 30.0 kg/m2 or above.
Measured: Baseline to 12 weeks
Change in waist-to-hip-ratio
Change from Baseline to 12 weeks. Measure of the ratio of the circumference of the waist and hip (unitless) measured by a flexible tape measure. For females, a value of <0.85 is ideal with values above this threshold being unfavorable. For males, a value of <0.90 is ideal with values above this threshold being unfavorable.
Measured: Baseline to 12 weeks
Change in total body fat percentage
Change from Baseline to 12 weeks. Estimate of body fat as a percent of total body weight (percent) measured by bioelectrical impedance analysis. Generally, for females, a value of 8-30% would be considered acceptable, and above 30% is considered unfavorable (overweight or obese). Generally, for males, a value of 5-20% would be considered acceptable, and above 20% is considered unfavorable (overweight or obese).
Measured: Baseline to 12 weeks
Change in fat mass
Change from Baseline to 12 weeks. Estimate of fat mass in the body (pounds) measured by bioelectrical impedance analysis. Higher values suggest higher fat mass in the body (typically an unfavorable finding) while lower values are suggestive of lower fat mass in the body (typically a favorable finding).
Measured: Baseline to 12 weeks
Change in fat free mass
Change from Baseline to 12 weeks. Estimate of non-fat mass in the body (pounds) measured by bioelectrical impedance analysis. Typically, higher values indicate more fat free mass (favorable) and lower values indicate less fat free mass (unfavorable).
Measured: Baseline to 12 weeks
Change in skeletal muscle mass
Change from Baseline to 12 weeks. Estimated weight of skeletal muscle in the body (pounds) measured by bioelectrical impedance analysis. Typically, a higher value indicates more skeletal muscle mass (favorable) while a lower value indicates less skeletal muscle mass (unfavorable).
Measured: Baseline to 12 weeks
Change in estimated maximal oxygen consumption (VO2)
Change from Baseline to 12 weeks. Difference in estimated maximal oxygen uptake (mL/kg/min), reflecting changes in cardiovascular fitness. Estimated maximum oxygen uptake (milliliters of oxygen per kilogram of body weight per minute) derived from a submaximal modified Balke treadmill test. Higher values are better for this measurement. Poorer outcomes vary for females and males and by age groups. Females VO2 Max that is considered poor: 18-29 yrs= <34 mL·kg-¹·min-¹, 30-39 yrs= <26 mL·kg-¹·min-¹, 40-49 yrs= <23 mL·kg-¹·min-¹, 50-59 yrs= <21 mL·kg-¹·min-¹, 60-65 yrs= <18 mL·kg-¹·min-¹. Males VO2 Max that is considered poor: 18-29 yrs= <43 mL·kg-¹·min-¹, 30-39 yrs= <37 mL·kg-¹·min-¹, 40-49 yrs= <32 mL·kg-¹·min-¹, 50-59 yrs= <25 mL·kg-¹·min-¹, 60-65 yrs= <22 mL·kg-¹·min-¹.
Measured: Baseline to 12 weeks
Change in 1-repetition maximum testing - Seated chest press
Change from Baseline to 12 weeks. A measure of muscular strength (in pounds), determined through a 1-repition maximum test using a seated chest press machine. A higher weight indicates higher muscular strength.
Measured: Baseline to 12 weeks
Change in 1-repetition maximum testing - Seated leg press
Change from Baseline to 12 weeks. A measure of muscular strength (in pounds), determined through a 1-repition maximum test using a seated leg press machine. A higher weight indicates higher muscular strength.
Measured: Baseline to 12 weeks
Change in time-based muscular endurance tests - wall sit
Change from Baseline to 12 weeks. Duration of maintaining a position (seconds) measured by performing a wall sit. A longer duration would indicate better muscular endurance.
Measured: Baseline to 12 weeks
Change in Time-based muscular endurance test - plank
Change from Baseline to 12 weeks. Duration of maintaining a position (seconds) measured by performing a plank hold. A longer duration maintaining good form in a plank position would indicate better muscular endurance.
Measured: Baseline to 12 weeks
Change in count-based muscular endurance test - push-up test
Change from Baseline to 12 weeks. Maximum number of repetitions of push-ups performed in one session (count), measured by performing push-ups until fatigue. A higher count would indicate better muscular endurance.
Measured: Baseline to 12 weeks
Change in upper body flexibility
Change from Baseline to 12 weeks. Shoulder and hamstring/low back flexibility (centimeters), measured by a back scratch and sit-and-reach test. A positive value would indicate better upper body flexibility, while a negative value would indicate worse upper body flexibility.
Measured: Baseline to 12 weeks
Change in lower body flexibility
Change from Baseline to 12 weeks. Hamstring and low back flexibility (centimeters), measured by a sit-and-reach test. Higher values indicate better lower body flexibility.
Measured: Baseline to 12 weeks
Change in perceived stress
Change from Baseline to 12 weeks. A score is determined from responses to the Perceived Stress Scale survey. Scores range from 0 to 40, with 0-13 typically indicating low stress, 14-26 moderate stress, and 27-40 high stress.
Measured: Baseline to 12 weeks
Change in perceived depressive symptoms
Change from Baseline to 12 weeks. A score is determined from responses to the Center for Epidemiological Studies Depression Scale-Short Form. Scores range from 0-20 with higher values indicating greater depressive symptoms.
Measured: Baseline to 12 weeks
Change in perceived sleep
Change from Baseline to 12 weeks. A global score is determined from responses to the Pittsburgh Sleep Quality Index Questionnaire. Scores range from 0 to 21 with a score of 5 or higher suggestive of sleep difficulties.
Measured: Baseline to 12 weeks
Change in body image perception
Change from Baseline to 12 weeks. A score is determined from responses to the Body Self-Image Questionnaire Short Form. Scores can range from 27 to 135 with higher scores suggesting more body image dissatisfaction.
Measured: Baseline to 12 weeks
Change in perceived anxiety symptoms
Change from Baseline to 12 weeks. A score is determined from responses to the Generalized Anixety Disorder-7 survey. Scores range from 0 to 21 with higher values represting more anxiety symptoms.
Measured: Baseline to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2025
- Study start1 Aug 2025
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by West Virginia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- West Virginia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bethany Barone Gibbs, West Virginia University
- Investigators
- Bethany Barone Gibbs, PhD, Principal investigator, West Virginia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06961981
- Sponsor's protocol ID
- 2410052950
- Status last verified
- Jul 2026
- First submitted
- 29 Apr 2025
- Last updated
- 7 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility, Acceptability, and Preliminary Efficacy of a Remote Vinyasa Yoga Program for Heart Health
- ClinicalTrials.gov ID
- NCT06961981
- Acronym / sponsor ID
- 2410052950
- Conditions
- Hypertension, Cardiovascular Diseases
- Keywords
- Yoga, vinyasa yoga
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- West Virginia UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 8 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test a 12-week vinyasa yoga (flow yoga) intervention via Zoom. This program will be for 30 individuals with high blood pressure. 15 will receive the intervention and 15 will follow their usual routine. The investigators will determine if this vinyasa yoga program is feasible and acceptable in this population. Investigators will measure and compare blood pressure and other health responses such as physical health and well-being before and after participants complete the intervention or usual care period. The investigators hope to demonstrate that vinyasa yoga is a good option to improve heart health in people with high blood pressure.
Primary Objective - Examine the feasibility, acceptability, and preliminary efficacy of a 12-wk remotely-delivered vinyasa yoga intervention (3 x per week) on cardiovascular (CV) health in adults with hypertension (HTN).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vinyasa Yoga | Experimental | Behavioral: Vinyasa YogaParticipants will complete a 12-week, remotely-delivered intervention with three 60-minute vinyasa yoga sessions per week via Zoom, following an adapted Journey into Power yoga sequence by Baron Baptiste. The sessions will incorporate three mind-body components of yoga: through physical yoga poses, mindfulness, and breathing. |
| Standard Routine | No intervention | –Standard usual routine for 12 weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Individuals with a resting systolic BP >120 mmHg
Key exclusion criteria (8 listed)
- Report currently meeting aerobic activity guidelines (150 min/wk)
- Practice yoga regularly (1 or more day/wk in the past month)
- Have physical limitations or a major medical condition contraindicating yoga or assessments
- Have uncontrolled HTN (systolic BP 160 mmHg or diastolic BP 100 mmHg)
- Are currently pregnant or planning to become pregnant within 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vinyasa YogaAlso: Flow YogaEach yoga session will begin with 2 minutes of integration poses (Child's Pose, Downward Facing Dog, Ragdoll, and Mountain Pose), followed by ~20 minutes of Sun Salutations A and B (up to 5 of each). The Standing Series, lasting ~25 minutes, will include various standing and balancing poses from the Journey into Power sequence. Seated and supine stretches (including seated stretches, a yoga inversion, a reclined twist) will last ~8 minutes, and the session will conclude with 5 minutes of Savasana for final relaxation. | Behavioural | Vinyasa Yoga |
Primary outcome
Change in Carotid-Femoral Pulse Wave Velocity
Time frame: Baseline to 12 weeks
Change from baseline to 12 weeks. Measure of central arterial stiffness (meters/second) measured by oscilometiric pulse wave velocity. A value of 10 m/s and above is classified as an unfavorable value.
29 secondary outcomes
Change in systolic blood pressure
Time frame: Baseline to 12 weeks
Change in diastolic blood pressure
Time frame: Baseline to 12 weeks
Change in augmentation pressure
Time frame: Baseline to 12 weeks
Change in augmentation index
Time frame: Baseline to 12 weeks
Change in mean heart rate
Time frame: Baseline to 12 weeks
Change in standard deviation of normal R-R Intervals
Time frame: Baseline to 12 weeks
Change in root mean square of successive differences
Time frame: Baseline to 12 weeks
Change in high frequency heart rate variability
Time frame: Baseline to 12 weeks
Change in low frequency heart rate variability
Time frame: Baseline to 12 weeks
Change in low frequency to high frequency ratio
Time frame: Baseline to 12 weeks
Change in body mass index
Time frame: Baseline to 12 weeks
Change in waist-to-hip-ratio
Time frame: Baseline to 12 weeks
Change in total body fat percentage
Time frame: Baseline to 12 weeks
Change in fat mass
Time frame: Baseline to 12 weeks
Change in fat free mass
Time frame: Baseline to 12 weeks
Change in skeletal muscle mass
Time frame: Baseline to 12 weeks
Change in estimated maximal oxygen consumption (VO2)
Time frame: Baseline to 12 weeks
Change in 1-repetition maximum testing - Seated chest press
Time frame: Baseline to 12 weeks
Change in 1-repetition maximum testing - Seated leg press
Time frame: Baseline to 12 weeks
Change in time-based muscular endurance tests - wall sit
Time frame: Baseline to 12 weeks
Change in Time-based muscular endurance test - plank
Time frame: Baseline to 12 weeks
Change in count-based muscular endurance test - push-up test
Time frame: Baseline to 12 weeks
Change in upper body flexibility
Time frame: Baseline to 12 weeks
Change in lower body flexibility
Time frame: Baseline to 12 weeks
Change in perceived stress
Time frame: Baseline to 12 weeks
Change in perceived depressive symptoms
Time frame: Baseline to 12 weeks
Change in perceived sleep
Time frame: Baseline to 12 weeks
Change in body image perception
Time frame: Baseline to 12 weeks
Change in perceived anxiety symptoms
Time frame: Baseline to 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
Related trials for Hypertension
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bethany Barone Gibbs, PhD principal investigator
West Virginia University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vinyasa Yoga in people with Hypertension and Cardiovascular Diseases, run by West Virginia University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Carotid-Femoral Pulse Wave Velocity (time frame: Baseline to 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.